Drug Trial Radar · NCT07197307
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 31, 2025
Primary completion
Apr 30, 2030
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Universität MünsterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbbVie; Sobi, Inc.
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Conditions
- Aggressive Diffuse Large B-cell Lymphoma
- High-grade B-cell Lymphoma (HGBL)
- Follicular Lymphoma (FL) Grade 3B
Interventions
Loncastuximab Tesirine and EpcoritamabDrug
Loncastuximab tesirine: Loncastuximab tesirine 150 µg/kg iv for 2 cycles followed by 75 µg/kg iv on day 1 of each 21-day cycle in responding patients for 4 cycles subsequently (max. 6 cycles). Epcoritamab: Step-up dosing for epcoritamab sc will be performed, consisting of a 0.16 mg sc priming dose on day 1 of cycle 1 (day 8 of cycle 1 for loncastuximab tesirine), followed by a 0.8 mg sc dose on day 8, and full dosing with 48 mg sc on day 15. Starting from day 15, epcoritamab will be administered weekly during cycle 2-3, then once every 2 weeks during cycle 4-9, and once every 4 weeks from cycle 10 until cycle 13 (max. 13 cycles).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best overall response rate (BORR)Time frame: 12 months after the start of study therapy
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Universitaetsklinikum Aachen
Aachen, Germany · Recruiting
Universitaetsklinikum Augsburg
Augsburg, Germany · Recruiting
Vivantes Netzwerk fuer Gesundheit
Berlin, Germany · Recruiting
Charite Universitaetsmedizin Berlin
Berlin, Germany · Recruiting
HELIOS Klinikum Berlin-Buch
Berlin, Germany · Recruiting
Evangelisches Klinikum Bethel
Bielefeld, Germany · Recruiting
Klinikum Chemnitz
Chemnitz, Germany · Recruiting
Universitaetsklinikum Duesseldorf
Düsseldorf, Germany · Recruiting
Universitaetsklinikum Erlangen
Erlangen, Germany · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Not yet recruiting
Universitaetsklinikum Frankfurt
Frankfurt, Germany · Recruiting
Medical Center - University Of Freiburg
Freiburg im Breisgau, Germany · Recruiting
Universitaetsmedizin Greifswald
Greifswald, Germany · Recruiting
Universitaetsklinikum Halle (Saale)
Halle, Germany · Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Germany · Not yet recruiting
St. Barbara-Klinik Hamm
Hamm, Germany · Recruiting
Universitaetsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Universitaet Des Saarlandes
Homburg, Germany · Recruiting
Universitaetsklinikum Jena
Jena, Germany · Recruiting
Staedtisches Klinikum Karlsruhe
Karlsruhe, Germany · Recruiting
Universitaetsklinikum Schleswig-Holstein
Kiel, Germany · Recruiting
Universitaetsklinikum Schleswig-Holstein
Lübeck, Germany · Recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, Germany · Recruiting
Philipps-Universitaet Marburg
Marburg, Germany · Recruiting
Muehlenkreiskliniken
Minden, Germany · Recruiting
Klinikum der Universitaet Muenchen
München, Germany · Not yet recruiting
Universitätsklinikum Münster, Medizinische Klinik A
Münster, Germany · Recruiting
Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts
Mutlangen, Germany · Recruiting
Ortenau Klinikum
Offenburg, Germany · Recruiting
Klinikum Oldenburg
Oldenburg, Germany · Recruiting
Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn
Paderborn, Germany · Recruiting
Universitaetsklinikum Regensburg
Regensburg, Germany · Recruiting
Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe
Stuttgart, Germany · Not yet recruiting
Universitaetsklinikum Ulm
Ulm, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.